Polycystic kidney disease

Autosomal Dominant Polycystic Kidney Disease Epiomic Epidemiology Report: Forecast In 29 Major Markets 2018-2028

Retrieved on: 
Friday, May 11, 2018
Kidney diseases, Medicine, Autosomal dominant polycystic kidney disease, Polycystic kidney disease, Clinical medicine, Genetics, Monogenic, Genetic disorder, Kidney, Polycystic disease, Polycystic kidney disease 3, Potter sequence

The "Epiomic Epidemiology Series: Autosomal Dominant Polycystic Kidney Disease Forecast In 29 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epiomic Epidemiology Series: Autosomal Dominant Polycystic Kidney Disease Forecast In 29 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary monogenic disorder characterised by the formation of renal cysts.
  • ADPKD is one of the most common hereditary disorders, and the most common potentially fatal monogenetic disease.
  • These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Avella Selected by Otsuka to distribute JYNARQUE

Retrieved on: 
Friday, April 27, 2018
Kidney diseases, Otsuka Pharmaceutical, Avella Specialty Pharmacy, Specialty drugs, Medicine, Chemistry, Autosomal dominant polycystic kidney disease, Tolvaptan, Polycystic kidney disease, Pharmacy, Specialty pharmacy, Health

PHOENIX, April 27, 2018 /PRNewswire/ -- Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD).

Key Points: 
  • PHOENIX, April 27, 2018 /PRNewswire/ -- Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD).
  • Headquartered in Phoenix, Arizona, Avella Specialty Pharmacy is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996.
  • In 2016, Avella was named Specialty Pharmacy of the Year by NASP, a nationally recognized pharmacy trade committee.
  • In addition, the Arizona Corporate Excellence Awards named Avella Specialty Pharmacy as the second fastest-growing private company based in the state in 2016.

JYNARQUE™ Approved as First Treatment for Polycystic Kidney Disease

Retrieved on: 
Tuesday, April 24, 2018
Kidney diseases, Polycystic kidney disease, Medicine, PKD, Anatomy, Polycystic disease, Kidney, Clinical medicine, Critical Path Institute, Autosomal dominant polycystic kidney disease

The PKD Foundation not only supported early studies that lead to the development of JYNARQUE as a treatment, but also helped guide PKD patients to the JYNARQUE clinical trials.

Key Points: 
  • The PKD Foundation not only supported early studies that lead to the development of JYNARQUE as a treatment, but also helped guide PKD patients to the JYNARQUE clinical trials.
  • JYNARQUE slows the growth of cysts and the progression of the disease and has been shown to preserve kidney function.
  • The PKD Foundation has been dedicated since its founding in 1982 to supporting and improving the lives of patients affected by polycystic kidney disease.
  • We fund research, advocate for patients and build a community for all affected by polycystic kidney disease (PKD).